Dogwood Therapeutics (DWTX) Intangibles (2024 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Intangibles of $67.8 million for Q1 2026, up 3.14% year-over-year from $65.8 million in Q1 2025, and down 1.67% quarter-over-quarter from $69.0 million in Q4 2025.
Dogwood Therapeutics (DWTX) Intangibles (2024 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Intangibles for 3 consecutive years, with $67.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 3.14% year-over-year to $67.8 million; the TTM figure through Mar 2026 stood at $67.8 million (up 3.14% YoY), while the FY2025 annual figure was $69.0 million, up 4.98% from the prior year.
- Intangibles retreated to $67.8 million in Q1 2026 per DWTX's latest filing, from $69.0 million in the prior quarter.
- Across five years, Intangibles topped out at $69.3 million in Q2 2025 and bottomed at $65.7 million in Q4 2024.
- Historically, Intangibles has averaged $67.6 million across 3 years, with a median of $67.9 million in 2025.
- Annual changes were most pronounced in 2025 — Intangibles gained 4.98% — and 2026, when it gained 3.14%.
- Dogwood Therapeutics' Intangibles stood at $65.7 million in 2024, then increased by 4.98% to $69.0 million in 2025, then decreased by 1.67% to $67.8 million in 2026.
- Business Quant data shows DWTX's Intangibles at $67.8 million in Q1 2026, $69.0 million in Q4 2025, and $67.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 57.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.83 Mn |
| Dec 31, 2025 | 68.99 Mn |
| Sep 30, 2025 | 67.92 Mn |
| Jun 30, 2025 | 69.30 Mn |
| Mar 31, 2025 | 65.77 Mn |
| Dec 31, 2024 | 65.71 Mn |